News 1998 Army Science and Technology Master Plan



COMBAT HEALTH SUPPORT (Section J)

III.J.01—Shigella Vaccines.  By FY96, determine molecular features required for protective immunity against Shigella species. By FY97, select the best methodology for vaccine development. By FY97, transition to advanced development a candidate Shigella sonnei vaccine to protect 80 percent of immunized troops from dysentery caused by Shigella sonnei. By FY99, transition to advanced development a candidate Shigella flexneri vaccine to protect 80 percent of immunized troops from dysentery caused by Shegilla flexneri in deployed forces worldwide.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

COL W. H. Bancroft
MRMC
(301) 619–7567
DSN: 343–7567
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
(804) 734–0599
DSN: 687–0599

 

III.J.02—Vaccines for the Prevention of Malaria.  By FY00, transition to advanced development a vaccine process to prevent P. falciparum infection in 80 percent of immunized personnel. By FY02, transition to advanced development a vaccine to prevent P. vivax infection in 80 percent of immunized personnel. By FY96, transition to advanced development a candidate blood stage Plasmodium falciparum vaccine to reduce incidence of severe clinical malaria by 70 percent. By FY97, transition a vaccine to prevent P. falciparum infection in 70 percent of immunized troops. By FY98, transition to advanced development a candidate blood stage Plasmodium vivax vaccine to protect 70 percent of immunized troops from vivax malaria.

Supports: Army Modernization Plan, Medical Annex O–Project, Sustain and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

COL W. H. Bancroft
MRMC
(301) 619–7567
DSN: 343–7567
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
(804) 734–0599
DSN: 687–0599

 

III.J.04—Antiparasitic Drug Program.  By FY98, transition to advanced development antiparasitic drugs capable of preventing or treating malaria or leishmaniasis. Candidates include arteether (parenteral treatment of severe drug resistant malaria), FY96; topical paromomycin/gentamicin (cutaneous leishmaniasis treatment), FY96; Floxacrine analog (malaria treatment), FY98; antovoquone–proquanil (malaria prophylaxis), FY97; artelinic acid (malaria prophylaxis), FY01.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

COL W. H. Bancroft
MRMC
(301) 619–7567
DSN: 343–7567
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
(804) 734–0599
DSN: 687–0599

 

III.J.05—Dengue Virus Vaccines.  By FY99, select the best methodology for vaccine development. By FY 1, transition to advanced development a candidate polyvalent dengue virus vaccine to protect 8 percent of immunized troops from dengue fever caused by dengue virus types 1, 2, 3, and 4.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

COL W. H. Bancroft
MRMC
(301) 619–7567
DSN: 343–7567
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
(804) 734–0599
DSN: 687–0599

 

III.J.07—Minimizing Blood Loss and Optimizing Fluid Resuscitation.  Provide information and transition to development products to enhance capabilities for control of and resuscitation from hemorrhage. By FY96, complete evaluation of commercially available local hemostatic agents to assess potential for field use in controlling bleeding; determine whether nondevelopmental item investment strategy is appropriate or if additional research and development are needed. By FY96, transition to development a field intraosseous infusion device. By FY96, transition to development an improved thawed or fresh blood preservative. By FY97, transition to development a field–portable fluid infusion–warming device suitable for battlefield use. By FY98, define mechanisms of toxicity of blood substitutes and complete evaluation of status of commercial blood substitute development to define future research and development needs. By FY00, define optimum perfusion pressures for hemorrhaging individuals.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force—Far Forward Surgical Care. Products include an advanced resuscitation solution, oxygen–carrying blood substitute, advanced physiologic sensors, more wound dressings, advanced physiologic sensors, novel wound dressings, and intraosseous infusion device. Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

MAJ Steve Brutigg
MRMC
(301) 619–7591
DSN: 343–7591
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
(804) 734–0599
DSN: 687–0599

 

III.J.08—Treatments to Prevent Secondary Damage After Hemmorhage or Major Injury. Transition to development or operational use the materiel and information required to reduce complications and death resulting from massive blood loss or major injuries, including measures to minimize irreversible damage during potentially prolonged evacuation. By FY96, transition a pharmacologic intervention capable of blocking the early steps in development of brain and/or spinal cord injury that occur secondarily to trauma, reducing irreversible damage by at least 20 percent. By FY98, transition a pharmacologic intervention that will reduce ischemia/reperfusion injury by 20 percent under conditions in which definitive treatment is delayed by up to 24 hours. By FY00, transition an intervention that will prevent or reduce by 35 percent trauma induced immunosuppression and related sepsis.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force–Far Forward Surgical Care. Products include a therapeutic antibody for the treatment of sepsis and a recombinant delta opioid (DADLE) for use in the delay or prevention of multiple organ failure. Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

MAJ Steve Brutigg
MRMC
(301) 619–7591
DSN: 343–7591
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
(804) 734–0599
DSN: 687–0599

 

III.J.14—Nutritional Strategies. Identify and demonstrate nutritional strategies to maintain health and enhance soldier performance. Assess efficacy of selected nutrients, food components, and feeding strategies in enhancing physical and mental performance and promoting nutritional health of soldiers during sustained and continuous operations at all climatic extremes. By FY95, determine efficacy of modified garrison dining facility menus and nutritional health and fitness education materials in promoting the consumption of a healthy diet. By FY97, complete animal and human laboratory studies of selected performance–enhancing nutrients and food components (i.e., carbohydrate beverages, caffeine, tyrosine). By FY98, in collaboration with the Natick Research, Development and Engineering Center, conduct an initial field demonstration of performance–enhancing ration components.

Supports: Guidelines for development of performance optimizing rations; Army Modernization Plan, Medical Annex O–Project, Sustain, and Protect the Force—prevent environmental injury and degradation of soldier performance; DoD Executive Agent for Nutrition.

STO Manager

TSO

TRADOC POC

Dr. Fred Hegge
MRMC
(301) 619–7301
DSN: 343–7301
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
LTC Dunham
CSS–BL
(405) 442–5647
DSN: 639–5647

 

III.J.18—Medical Countermeasures for Yersinia pestis.  Develop medical CM against the biological threat of Yersinia pestis, the causative agent of plague. By FY95, complete an assessment of the efficacy of the Cutter vaccine against an aerosol challenge of Yersinia pestis. By FY98, transition to development a vaccine that will protect 80 percent of immunized personnel against an aerosol challenge of Yersinia pestis and will induce minimum reactogenicity in soldiers when immunized.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.19—Medical Countermeasures for Encephalitis Viruses. Develop medical CM against the biological warfare threat of the encephalitis viruses, a group of viruses that cause disorientation, convulsions, paralysis, and death. Vaccines will protect 80 percent of the immunized population against an aerosol exposure of the virus and will induce minimum reactogenicity in soldiers when immunized. By FY96, transition to development an improved vaccine effective against Venezuelan equine encephalomyelitis (VEE) virus stereotypes 1 A/B/C. By FY98, construct analogous vaccines for Eastern equine encephalitis (EEE) and Western equine encephalitis (WEE). By FY00, develop a multivalent VEE vaccine that includes serotypes 1E and III.

Supports: Army Modernization Plan Objectives, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.20—Medical Countermeasures for Brucellosis.  Develop medical countermeasures against the biological warfare threat of Brucella, the causative agent of brucellosis, a systemic bacterial disease characterized by fever, weakness, depression, and generalized aching. By FY97, demonstrate the feasibility of producing a vaccine against brucellosis using one species as the model approach (milestone 0). By FY99, transition to advanced development a vaccine that will protect 80 percent of immunized personnel against an aerosol challenge of any species of Brucella and will induce minimum reactogenicity in soldiers when immunized (milestone 1).

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.23—Medical Countermeasures for Ricin. Develop medical CM against the biological warfare threat of ricin toxin. By FY97, conduct a Milestone 0 transition of a second generation vaccine. By FY99, transition to advanced development a second generation vaccine that will protect 90 percent of the immunized population against an aerosol challenge and will induce minimum reactogenicity in soldiers when immunized (Milestone 1).

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.24—Medical Countermeasures for Staphylococcal Enterotoxin B (SEB).  Develop medical CM against the biological warfare threat of SEB toxin. By FY96, transition to advanced development a vaccine that will prevent 80 percent of the immunized animals from death against a lethal aerosol challenge of SEB (milestone 1 transition). By FY96, demonstrate the feasibility of producing a secondary generation vaccine that will protect 90 percent of the immunized animals against both a lethal and incapacitating aerosol challenge of SEB (Milestone 0 transition). By FY00, transition to advanced development the second generation vaccine (Milestone 1 transition).

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.25—Medical Countermeasures for Botulinum Toxin. Develop medical CM against the biological warfare threat of botulinum toxin. By FY97 transition to advanced development a recombinant vaccine that will protect 80 percent of immunized personnel against an aerosol challenge, provide protection against all serotypes, and induce minimum reactogenecity in immunized soldiers (milestone 1).

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.26—Reactive Topical Skin Protectant/Decontaminant.  By FY95, demonstrate proof of principle of the reactive topical skin protectant concept. By FY97, demonstrate efficacy of a reactive topical skin protectant. Demonstrate by FY99, safety and efficacy sufficient for a Milestone O transition of a reactive component for a topical skin protectant that will provide protection against penetration and will detoxify both vesicant and nerve chemical warfare agents.

Supports: Development of Food and Drug Administration–licensed reactive skin protectant; Program Manager–Soldier; Draft MNS (11 Sep 92); Operational and Organizational Plans (Feb 95, Aug 85, Dec 86, May 87, Aug 90); Joint Service Agreement (14 Dec 93) – Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures.

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Charles Campbell
MBS BL
(502) 624–1963
DSN: 464–1963

 

III.J.27—Medical Countermeasures Against Vesicant Agents.  By FY96, exploit pathophysiology database and new technologies for prophylaxis, pretreatment, and antidote strategies that will provide significant protection against vesicant injury. By FY97, demonstrate efficacy of a vesicant CM. Demonstrate by FY00, safety and efficacy of a candidate medical CM sufficient for a Milestone 0 transition.

Supports: Development of Food and Drug Administration–licensed protectants, pretreatments, and therapies for vesicant agents; Program Manager–Soldier; Operational and Organizational Plans (Mar 87); Draft MNS (11 Sep 92); Joint Service Agreement (14 Dec 93) – Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures.

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Charles Campbell
MBS BL
(502) 624–1963
DSN: 464–1963

 

III.J.29—Advanced Anticonvulsant.  By FY97, demonstrate safety and efficacy sufficient for a Milestone 0 transition of an advanced anticonvulsant adjunct or component for the soldier/buddy–use nerve agent antidote. Advanced anticonvulsant will overcome deficiencies of current anticonvulsant, Convulsant Antidote for Nerve Agent (CANA), i.e., will be more effective in stopping ongoing convulsive seizures, preventing their recurrence, and protecting against nerve–agent–induced, seizure–related brain damage. It will also demonstrate less abuse potential than CANA. Achieve Milestone 1 transition by FY99.

Supports: Development of Food and Drug Administration–licensed anticonvulsant for nerve agent therapy; Program Manager–Soldier; Operational and Organizational Plans (Mar 87); Draft MNS (11 Sep 92); Joint Service Agreement (14 Dec 93) – Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures.

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Charles Campbell
MBS BL
(502) 624–1963
DSN: 464–1963

 

III.J.30—Chemical Agent Prophylaxes.  By FY97, demonstrate the feasibility of a reactive/catalytic scavenger pretreatment effective against chemical agents. By FY99, demonstrate safety and efficacy sufficient for a Milestone 0 transition of a reactive/catalytic scavenger pretreatment that reduces chemical agent toxicity without operationally significant physiological or psychological side effects.

Supports: Development of Food and Drug Administration–licensed reactive/catalytic protectants for nerve agents; Program Manager–Soldier; Operational and Organizational Plans (Nov 86); Draft MNS (11 Sep 92); Joint Service Agreement (14 Dec 93) – Protect, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures.

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Charles Campbell
MBS BL
(502) 624–1963
DSN: 464–1963

 

III.J.31—Computer–Aided Diagnosis and Treatment.   This concept seeks to integrate all of the various individual soldier medically oriented advanced technology and route the data gathering, calculation, decision making and communication through the Soldier Individual Computer common to all 21st Century Land Warriors. This STO supports development of communication–enabled advanced technologies (both sensor and microprocessing) to support triage, diagnosis, treatment, casualty monitoring, and patient status awareness during enroute care. This research and development provides a seamless connection between local casualty assessment and treatment and telemedicine efforts to build an electronic medical record or mentor deployed health care providers. The approach is to develop medical overlays to tactical computing/communicating capability already under development, in order to assess performance without injury, and to compare data postinjury to preinjury "control" data for individualized injury severity assessment. Research efforts will develop a variety of noninvasive vital sign sensor (most utilizing infrared or near infrared technologies to determine deep tissue microvascular blood flow, tissue oxygenation, lactate and CO2 build–up and tissue. Additional efforts will develop interfaces and controllers between these sensors and the Soldier Individual Computer. Finally, R&D efforts will focus on the development of medical decision assist algorithms that will aid the combat medic in diagnosing and selecting appropriate treatments. Such algorithms will be capable of updating every minute to provide assessment of treatment effectiveness or continued medical threat. By FY98, transition to advanced validation studies of noninvasive vital sign sensors for combat trauma diagnostics and monitoring; by FY 00 transition vital sign sensor interface to Soldier Individual Computer (21CLW); by FY00, transition to advanced development a candidate medical decision assist algorithm;

Supports: Early Entry, Dismounted, Mounted, Battle Command and Combat Service Support Battle Labs. Supports Army Modernization Plan objectives "Project and Sustain the Force."

STO Manager

TSO

TRADOC POC

MAJ Steve Brutigg
MRMC
(301) 619–7591
DSN: 343–7591
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
Herbert Russakoff
CSS Battle Lab
804–734–0599
DSN: 687–0599

 

III.J.32—Biological Warfare Agent Confirmation Diagnostic Kit.  Develop the capability to confirm the initial field diagnosis obtained with the forward deployable diagnostic kit. These tests will differ from forward deployed tests by being more specific and more sensitive and by using independent biological markers. By FY98, transition to development confirmation techniques for all biological warfare (BW) agents in the theater of operations.

Supports: DEPSECDEF guidance (26 Aug 91); Joint Requirements Oversight Council guidance (31 Aug 92); Combat Service Support and Dismounted Battle Labs.

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.33—Filoviridae.  Develop medical CM against the biological warfare (BW) threat of Filoviridae, which includes Marburg virus and Ebola virus. By FY 01, transition to advanced development a bivalent vaccine effective against Marburg and Ebola viruses.

Supports: Army Modernization Plan Objectives, Medical Annex O, Project, Sustain, and Protect the force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.34—Medical Countermeasures for Variola.  Develop medical CM against the biological warfare threat of variola, the causative agent of smallpox. By FY97, confirm the use of an animal model for the purpose of demonstrating the efficacy of the current licensed vaccine against aerosol–delivered variola. By FY98, perform relevant preclinical testing of new cell culture–derived vaccinia vaccine directed towards variola. By FY99, develop rapid and highly specific diagnostic devices for clinical specimens. By FY00, explore the feasibility of using human monoclonal antibodies to replace vaccinia immune globulin (VIG). By FY01, screen and identify effective antiviral drugs for post–exposure treatment. Note: None of the studies conducted at USAMRIID will utilize variola itself, instead the studies will employ the use of an appropriate orthopox virus substitute.

Supports: Army Modernization Plan Objectives, Medical Annex O—Project, Sustain, and Protect the force by Development of NBC Agent Preventive Measures. Provides for the exploration, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.35—Multiagent Vaccines for Biological Threat Agents.  Description: Develop vaccine candidates that will concurrently provide protective immune response against a range of biological threat agents. Identify technologies that would permit multiple immunogens or nucleic acid based vaccine candidates to be combined in a single preparation with the endpoint of simultaneously immunizing recipients against multiple biological warfare threats. Demonstrate by FY 00 the feasibility of these approaches in appropriate animal models. Transition to advanced development (Milestone 1), by FY 02, a vaccine that protects 90 percent or more of immunized animals from death or incapacitation by specific agents, as appropriate, following exposure to aerosol delivery of agents at equivalent doses to those anticipated under operational settings.

Supports: Army Modernization Plan Objectives, Medical Annex O—Project, Sustain, and Protect the Force by Development of NBC Agent Preventive Measures. Provides for the exporation, demonstration, and validation of biological defense vaccines as outlined by the DEPSECDEF (26 Aug 91) and the Joint Requirements Oversight Council (31 Aug 92).

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.36—Common Diagnostic Systems for Biological Threats and Endemic Infectious Disease.   Develop diagnostic assays and reagents that will provide rapid laboratory diagnosis for a broad array of biological threats and infectious diseases, using common diagnostic technologies. Identify technologies that allow for forward and confirmatory laboratory diagnosis regardless of the etiological agent. By FY98, demonstrate the feasibility of common diagnostic systems for biological threats and infectious diseases. Identify genetic and immunological targets for emerging diagnostic systems technology for biological threats and infectious diseases. By FY02, transition to advanced development common diagnostic systems for biological threats and infectious diseases.

Supports: DEPSECDEF guidance (26 Aug 91); Joint Requirements Oversight Council guidance (31 Aug 92); Combat Service Support and Dismounted Battle Labs.

STO Manager

TSO

TRADOC POC

COL Gerald Parker
MRMC
(301) 619–7439
DSN: 343–7439
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

 

III.J.37p—Novel Antiparasitic Drug Development.   Provide development of novel compounds and transition to advanced development drugs capable of preventing or treating emerging drug resistant strains of parasitic diseases including malaria and leishmaniasis. This will result in sustained readiness by reducing loss of manpower due to illness caused by malaria and other diseases. Technical barriers include a continuing effort to keep up with multi–drug resistant malaria, determining mechanisms of drug–resistance and development of new animal and in vitro models. By FY03, identify new classes of compounds for the prevention and treatment of malaria. This will include testing to determine whether 80% of a population will be protected by pyridine methanol.

Supports: Army Modernization Plan, Medical Annex O—Project, Sustain and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.

STO Manager

TSO

TRADOC POC

Col. Charles Hoke
MRMC
(301) 619–7439
DSN: 343–7567
LTC Bill Pratt
SARD–TM
(703) 695–8443
DSN: 225–8443
CPT Ensor
CSS–BL
(706) 545–5994
DSN: 835–5994

Click here to go to next page of document